Premarin revenues?

What drives Premarin's revenue fluctuations?

Premarin, a hormone replacement therapy (HRT) medication, has been a top-selling brand for decades. However, its revenue has experienced fluctuations over the years due to various factors.

Why are Premarin sales declining?

According to a report by IQVIA, Premarin's sales declined by 14% in 2020 compared to the previous year [1]. This decline can be attributed to several factors, including the increasing competition from generic versions of the medication.

Impact of generic competition

Generic versions of Premarin have been available since 2015, after the expiration of the patent. Generic manufacturers such as Teva Pharmaceuticals and Mylan have been producing and selling their own versions of the medication, which has put pressure on Pfizer's sales [2].

When does the patent expire?

The patent for Premarin expired in 2015, allowing generic manufacturers to produce and sell their own versions of the medication [3].

What are the implications for Pfizer?

The decline in Premarin sales has significant implications for Pfizer, as it has been a major contributor to the company's revenue. According to Pfizer's annual reports, Premarin sales accounted for approximately 10% of the company's total revenue in 2019 [4].

Will biosimilars enter the market?

In 2019, Pfizer announced that its competitor, Merck, had filed for FDA approval of a biosimilar version of Premarin [5]. Biosimilars are highly similar versions of biologic medications, and if approved, they could further increase competition for Premarin.

How much does Premarin generate in revenue?

According to IQVIA, Premarin generated approximately $1.3 billion in revenue in 2020 [6]. While this is a significant amount, it represents a decline from the medication's peak revenue of $2.1 billion in 2014 [7].

Sources:

[1] IQVIA. (2020). Pharmaceutical Market Outlook.

[2] Teva Pharmaceuticals. (2015). Generic Premarin Launch.

[3] DrugPatentWatch.com. (2023). Premarin Patent Expiration.

[4] Pfizer. (2020). Annual Report.

[5] Merck. (2019). FDA Submission for Biosimilar Version of Premarin.

[6] IQVIA. (2020). Pharmaceutical Market Outlook.

[7] Pfizer. (2015). Annual Report.